-
Medical Devices Industry Outlook - Dec. 2010 - Industry Outlook
Monday, December 6, 2010 - 6:30pm | 3167Industry Dynamics The global medical devices industry is fairly large, intensely competitive and highly innovative with 2009 worldwide sales in excess of $220 billion. The U.S. accounts for approximately 41% of this market. The industry is divided into different segments such as Cardiology,...
-
Medical Devices Industry Outlook – Dec. 2010 - Industry Outlook
Monday, December 6, 2010 - 6:30pm | 3167Industry Dynamics The global medical devices industry is fairly large, intensely competitive and highly innovative with 2009 worldwide sales in excess of $220 billion. The U.S. accounts for approximately 41% of this market. The industry is divided into different segments such as Cardiology,...
-
Medical Devices Industry Outlook – Dec. 2010 - Industry Outlook
Monday, December 6, 2010 - 5:57pm | 3167Industry Dynamics The global medical devices industry is fairly large, intensely competitive and highly innovative with 2009 worldwide sales in excess of $220 billion. The U.S. accounts for approximately 41% of this market. The industry is divided into different segments such as Cardiology,...
-
Positive Data on Shire's Firazyr - Analyst Blog
Monday, December 6, 2010 - 3:08pm | 380Shire plc (SHPGY) recently announced that it met its goals in the FAST 3 trial that was conducted with its hereditary angioedema (HAE) treatment, Firazyr. Hereditary angioedema is a rare genetic disease characterized by acute swelling of the hands, feet, face and larynx. Firazyr is an injectable...
-
Positive Data on Shire's Firazyr - Analyst Blog
Monday, December 6, 2010 - 1:51pm | 380Shire plc (SHPGY) recently announced that it met its goals in the FAST 3 trial that was conducted with its hereditary angioedema (HAE) treatment, Firazyr. Hereditary angioedema is a rare genetic disease characterized by acute swelling of the hands, feet, face and larynx. Firazyr is an injectable...
-
Citigroup Increases Cooper Companies EPS Estimates
Monday, December 6, 2010 - 8:51am | 50Citigroup has increased its EPS estimates on shares of Cooper Companies, Inc. (NYSE: COO) from $2.84 to $2.90 for F10 and from $3.15 to $3.25 for F11. “We will revisit our financial model/targets after this Tuesday's earnings report,” Citigroup writes. Cooper Companies closed Friday at $53.55.
-
Medical Devices Industry Outlook - Dec. 2010 - Industry Outlook
Monday, December 6, 2010 - 1:00am | 3167Industry Dynamics The global medical devices industry is fairly large, intensely competitive and highly innovative with 2009 worldwide sales in excess of $220 billion. The U.S. accounts for approximately 41% of this market. The industry is divided into different segments such as Cardiology,...
-
Medical Devices Industry Outlook - Dec. 2010 - Zacks Analyst Interviews
Monday, December 6, 2010 - 1:00am | 3167Industry Dynamics The global medical devices industry is fairly large, intensely competitive and highly innovative with 2009 worldwide sales in excess of $220 billion. The U.S. accounts for approximately 41% of this market. The industry is divided into different segments such as Cardiology,...
-
Align Downgraded to Neutral - Analyst Blog
Thursday, December 2, 2010 - 3:00pm | 550Recently, we downgraded Align Technology (ALGN) to Neutral with a target price of $18.00. Align manufactures and markets the Invisalign system, a proprietary method for treating malocclusion or misalignment of teeth. The system corrects malocclusion using some nearly invisible and removable...
-
Align Downgraded to Neutral - Analyst Blog
Thursday, December 2, 2010 - 9:21am | 550Recently, we downgraded Align Technology (ALGN) to Neutral with a target price of $18.00. Align manufactures and markets the Invisalign system, a proprietary method for treating malocclusion or misalignment of teeth. The system corrects malocclusion using some nearly invisible and removable...
-
Align to Resolve Warning Letter Issue - Analyst Blog
Wednesday, December 1, 2010 - 5:01pm | 525Align Technology (ALGN) received a warning letter from the US Food and Drug Administration (FDA) on November 18 requesting additional documentation over and above its response provided earlier related to the inspection of its corporate headquarters in California (between June and August). The FDA...
-
Align to Resolve Warning Letter Issue - Analyst Blog
Wednesday, December 1, 2010 - 11:35am | 525Align Technology (ALGN) received a warning letter from the US Food and Drug Administration (FDA) on November 18 requesting additional documentation over and above its response provided earlier related to the inspection of its corporate headquarters in California (between June and August). The FDA...
-
Piper Jaffray Neutral On Santarus (SNTS)
Wednesday, December 1, 2010 - 8:25am | 164Piper Jaffray has a Neutral rating on Santarus Inc. (NASDAQ: SNTS) and a $3.50 price target after the company presented at a Piper Jaffray conference. In a note sent to clients, Piper Jaffray writes, "Yesterday, Santarus presented at the Piper Jaffray Healthcare Conference. Management provided...
-
Watch Key Support Levels 11-30-2010
Tuesday, November 30, 2010 - 7:36pm | 869Cusick's Corner The data flow over the next 24 hours has the potential to add some additional volatility into these markets. Watching key support levels will be essential. Since the bulls are in control any tip below 1170 in the S&P would indicate that a temporary shift in momentum is upon...
-
Good News for Merit Medical - Analyst Blog
Tuesday, November 30, 2010 - 5:30pm | 433Recently, Merit Medical Systems (MMSI) received approval from the US Food and Drug Administration (FDA) for the phase III clinical trial protocol to treat primary liver cancer with QuadraSphere microsphere for delivery of doxorubicin. The approval is significant since the late-stage study in...